Leerink Partners maintains Outperform rating on AnaptysBio, $81 price target

Leerink Partners maintained their Outperform rating on AnaptysBio's stock with a price target of $81.00.The price target implies an upside of 50.2% from the Sep 22 close of $53.92.Key takeaways from the analyst noteStrong Pipeline Development: AnaptysBio is advancing multiple immune cell modulating…